| CMS | children's medical services; Christian Medical Society; chronic myelodysplastic syndrome; chromosome... |
|---|---|
| EBM | electrophysiologic behavior modification; epidermal basement membrane; evidence-based medicine; expr... |
| ICD-9-CM | International Classification of Diseases-ninth revision-Clinical Modification |
| MDRD | Modification of Diet in Renal Disease [study] |
| mod | moderate, moderation; modification |
| antigen-combining site | See: paratope. (05 Mar 2000) |
|---|---|
| antigen excess | In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases. (05 Mar 2000) |
| antigen interferon | <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation. This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity. Synonym: antigen interferon, immune interferon. Pharmacological action: antineoplastic agent, antiviral agents. (20 Sep 2002) |
| antigen p150,95 | A major adhesion-associated heterodimer molecule expressed by human monocytes, granulocytes, nk cells, and some lymphocytes. The alpha subunit is the CD11c antigen (also called leu-m5), a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 antigen (antigens, CD18). The p150,95 antigen has been shown to play an important role in cell-cell and cell-substrate adhesive interactions. (12 Dec 1998) |
| antigen presentation | A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin. See: MHC restriction, histocompatibility antigens. (18 Nov 1997) |
| antigen presenting cell | A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin. See: MHC restriction, histocompatibility antigens. (18 Nov 1997) |
| antigen-presenting cells | Immunocompetent cells, usually ia positive, that mediate the cellular immune response by processing and presenting antigens or mitogens which stimulate T-cell activation. (12 Dec 1998) |
| antigen processing | Modification of an antigen by accessory cells. This usually involves endocytosis of the antigen and either minimal cleavage or unfolding. The processed antigen is then presented in modified form by the accessory cell. (18 Nov 1997) |
| antigen-responsive cell | A small lymphocyte that, although not itself an immunologically activated cell, responds to antigenic (immunogenic) stimulus by a process of division and differentiation that results in the production of immunologically activated cells. Synonym: antigen-responsive cell. (05 Mar 2000) |
| antigen-sensitive cell | A small lymphocyte that, although not itself an immunologically activated cell, responds to antigenic (immunogenic) stimulus by a process of division and differentiation that results in the production of immunologically activated cells. Synonym: antigen-responsive cell. (05 Mar 2000) |
| antigen shift | Abrupt change in antigens expressed by a species or variety of organisms. Usually seen in microorganisms where the change may allow escape from immune recognition. Antigenic drift is a more gradual change. See: antigenic variation. (18 Nov 1997) |
| antigen unit | The smallest amount of antigen that, in the presence of specific antiserum, will fix 1 complement unit. (05 Mar 2000) |
| aspergillus antigen skin test | <investigation> An antigen, prepared from aspergillus, is injected into the skin. In 48 to 72 hours the site is read as positive or negative. A positive skin test (inflammation at the test site) indicates prior exposure to aspergillus and therefore a risk for developing aspergillosis. (27 Sep 1997) |
| Au antigen | Auberger blood group |
| Aus antigen | <virology> An envelope antigen now known as HBsAg of Hepatitis B virus. Appearance of the antigen in serum is associated with a phase of high infectivity. (18 Nov 1997) |